Venetoclax for Chronic Lymphocytic Leukaemia Patients Who Progress After More Than One B-cell Receptor Pathway Inhibitor

Overview

Journal Br J Haematol

Specialty Hematology

Date 2018 Nov 28

PMID 30478940

Citations 4

Authors

William G Wierda

John C Byrd

Matthew S Davids

Richard R Furman

Bruce D Cheson

Paul M Barr

Herbert Eradat

Leonard Heffner

Lang Zhou

Maria Verdugo

Jalaja Potluri

Michael Choi

Affiliations

Soon will be listed here.

Citing Articles

High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.

Ghia E, Rassenti L, Choi M, Quijada-Alamo M, Chu E, Widhopf 2nd G Leukemia. 2022; 36(6):1609-1618.

PMID: 35418613 PMC: 9162914. DOI: 10.1038/s41375-022-01543-y.

Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors.

Bose P, Gandhi V Fac Rev. 2021; 10:22.

PMID: 33718939 PMC: 7946394. DOI: 10.12703/r/10-22.

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.

Mato A, Ghosh N, Schuster S, Lamanna N, Pagel J, Flinn I Blood. 2020; 137(20):2817-2826.

PMID: 33259589 PMC: 8574211. DOI: 10.1182/blood.2020007376.

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.

Pula B, Golos A, Gorniak P, Jamroziak K Cancers (Basel). 2019; 11(12).

PMID: 31766355 PMC: 6966427. DOI: 10.3390/cancers11121834.

References

Hallek M, Cheson B, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-56. PMC: 2972576. DOI: 10.1182/blood-2007-06-093906. View

Howard S, Jones D, Pui C . The tumor lysis syndrome. N Engl J Med. 2011; 364(19):1844-54. PMC: 3437249. DOI: 10.1056/NEJMra0904569. View

Furman R, Sharman J, Coutre S, Cheson B, Pagel J, Hillmen P . Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370(11):997-1007. PMC: 4161365. DOI: 10.1056/NEJMoa1315226. View

Byrd J, Brown J, OBrien S, Barrientos J, Kay N, Reddy N . Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371(3):213-23. PMC: 4134521. DOI: 10.1056/NEJMoa1400376. View

Burger J, Tedeschi A, Barr P, Robak T, Owen C, Ghia P . Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 373(25):2425-37. PMC: 4722809. DOI: 10.1056/NEJMoa1509388. View